XORTX Therapeutics (XRTX) announces a presentation by Dr. Allen Davidoff at the Rare and Genetic Kidney Disease Summit, in Boston, Massachusetts at 10:30 am ET, Thursday December 12, 2024. The presentation entitled “Autosomal Dominant Polycystic Kidney Disease – Genetic and Environmental Factors Evidence for Aberrant Purine Metabolism as a Second Hit Determining Disease Progression.” The presentation highlights XORTX recent pioneering discoveries in the field of Autosomal Dominant Polycystic Kidney Disease, and recent peer-reviewed, independent, published research reports identifying genetic factors that influence over-expression of xanthine oxidase and play a role in several diseases, including kidney disease. These findings suggest that genetic factors that influence aberrant purine metabolism may influence the rate of progression of ADPKD.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XRTX:
- Xortx Therapeutics files to sell 810,810 common shares for holders
- XORTX Therapeutics Inc. Faces Financial Challenges
- XORTX Highlights Kidney Disease Study at ASN
- Xortx Therapeutics announces presentation of sponsored study at ASN Kidney Week
- XORTX Secures $1.5 Million in Latest Offering
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
